Bacil Pharma

Bacil Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bacil Pharma (524516.BO) as of Oct 29, 2026 is 45.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 97.51 % — a change of -53.09% (lower).

FCF Conversion

45.75 %

YoY

-53.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bacil Pharma is 2026 45.75 % . FCF Conversion Rate (FCF/EBITDA) of Bacil Pharma was 2025 97.51 % . It decreases by -53.09% lower compared to the previous year.

The Bacil Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-418.45 INR
Jan 1, 2020
120.01 INR
Jan 1, 2021
166.38 INR
Jan 1, 2022
103.86 INR
Jan 1, 2023
144.79 INR
Jan 1, 2024
4.91 INR
Jan 1, 2025
97.51 INR
Jan 1, 2026
45.75 INR
The Bacil Pharma FCF Conversion history
YEARFCF ConversionYoY
45.75 %-53.09%
97.51 %+1,885.68%
4.91 %-96.61%
144.79 %+39.41%
103.86 %-37.57%
166.38 %+38.64%
120.01 %-128.68%
-418.45 %+1,283.55%
-30.24 %-107.37%
410.38 %-94.69%
7,727.34 %-1,112.02%
-763.56 %-1,693.04%
47.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bacil Pharma Stock analysis

What does Bacil Pharma do? Bacil Pharma Ltd, identified by the ticker symbol 524516.BO and the ISIN INE711D01018, is a prominent entity within the Indian healthcare sector. Headquartered in Mumbai, Maharashtra, the company has established itself as a significant player in the pharmaceutical industry. Bacil Pharma Ltd specializes in the comprehensive manufacturing and distribution of a diverse range of products, including pharmaceuticals, medicinal chemicals, and botanical products. This strategic focus on both synthetic medicinal compounds and natural botanical ingredients allows the company to cater to a broad spectrum of therapeutic needs and market demands. The firm's operational base in Mumbai, one of India's major financial and commercial hubs, provides it with substantial logistical advantages and access to a well-developed infrastructure network, which is crucial for the timely distribution of healthcare products across the country and potentially into international markets. The company's journey in the public domain began with its initial public offering on March 15, 1994. This milestone marked a significant step in its corporate evolution, enabling it to raise capital for expansion, research, and development activities. Since its listing, Bacil Pharma Ltd has continued to refine its product portfolio and manufacturing capabilities, maintaining a steady presence in the competitive pharmaceutical landscape. The company's official website, http://www.bacilpharma.com/, serves as a primary resource for stakeholders, investors, and customers seeking detailed information about its product lines, corporate governance, and business operations. By engaging in the manufacture and sale of both medicinal and botanical products, Bacil Pharma Ltd demonstrates a commitment to integrating traditional herbal wisdom with modern pharmaceutical science. This dual approach not only reflects the growing global interest in natural health solutions but also positions the company to capitalize on emerging trends in preventive healthcare and wellness. As a listed entity on the Indian stock exchange, Bacil Pharma Ltd is subject to regulatory oversight and disclosure requirements, ensuring transparency and accountability to its shareholders. The company's enduring presence in the market since the mid-1990s underscores its resilience and adaptability in a dynamic industry characterized by rapid technological advancements and evolving regulatory frameworks. Through its continued focus on quality manufacturing and product innovation, Bacil Pharma Ltd aims to sustain its growth trajectory and contribute to the broader healthcare ecosystem in India and beyond. Bacil Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bacil Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Bacil Pharma is 45.75 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Bacil Pharma changed from 97.51 % to 45.75 %, representing a -53.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bacil Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bacil Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bacil Pharma

All Key Metrics — Bacil Pharma